BioCryst Pharmaceuticals
BCRX
BCRX
241 hedge funds and large institutions have $1.42B invested in BioCryst Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 39 funds opening new positions, 94 increasing their positions, 69 reducing their positions, and 24 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
6.19% more ownership
Funds ownership: 84.17% → 90.36% (+6.2%)
5% more funds holding
Funds holding: 230 → 241 (+11)
31% less capital invested
Capital invested by funds: $2.07B → $1.42B (-$650M)
Holders
241
Holding in Top 10
8
Calls
$25.4M
Puts
$9.49M
Top Buyers
| 1 | +$36.9M | |
| 2 | +$30.4M | |
| 3 | +$23.1M | |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$21.9M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$19.8M |
Top Sellers
| 1 | -$33M | |
| 2 | -$29.2M | |
| 3 | -$21M | |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
-$16.4M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$16.1M |